Join BrainsWay for a virtual Analyst and Investor Day during which company management will highlight various aspects of BrainsWay’s growth strategy. The event will feature Owen Scott Muir, MD, DFAACAP (Co-Founder, Chief Medical Officer, Radial), who will discuss the significant unmet need for various conditions and his clinical experience utilizing Deep TMS™, and Michael Gershenzon, CEO of Stella MSO, a management services organization servicing more than 20 mental health clinics across the U.S. and Israel, who will discuss his experience working with BrainsWay on BrainsWay’s strategic minority-stake investment in Stella.

The event will provide an overview of BrainsWay’s patented breakthrough treatment, Deep TMS, and the potential impact of its accelerated protocol. Deep TMS is a clinically proven, noninvasive in-office brain stimulation treatment that uses magnetic fields to activate neural networks in the brain to improve symptoms of certain mental health and addiction conditions, including depression, obsessive-compulsive disorder, and smoking addiction.

A live question and answer session will follow the formal presentations.